Sanwa Kagaku Kenkyusho Co., Ltd.

Telik, Inc.

Mitsuaki Takeuchi

Kouji Matsushima

Hugo O Villar

Yoshiro Ishiwata

Louise Robinson

Edgardo Laborde

Yukiharu Matsumoto

Takuji Kakigami

Shoji Yokochi

Brian T Peterson

Fanying Meng

Hiroki Nagano

Steven E Anuskiewicz

Mitsuru Oka

Hideaki Inagaki

Yuji Hayashi

Masahiro Shirai

Wenli Ma

Masahiro Yoshida

Mitsuhiro Makino

Motohiro Takeda

Yuka Kuno

Toshiyuki Miyazawa

Daisuke Kurumazuka

Satoko Harada

Toru Izuchi

Morio Okabe

Yukiyasu Asano

Atsushi Miyachi

Takashi Nakamura

Masayuki Okamoto

Katsumasa Tanaka

Kunihisa Baba

Katsunori Kitamoto

Nobuyoshi Kasugai

Hiroyo Kataoka

Yasushi Ohsawa

Hiroki Fujieda

Keita Sakai

Takayo Murase

Masao Sakairi

Toru Murase

Naoki Takahashi

Noriyasu Katoh

Izumi Gotoh

Yurie Yamada

Takayo Yamamoto

A compound having a V2 receptor agonistic activity is provided. Providing a pharmaceutical composition which contains, as an active ingredient, a compound represented by general formula (I) described below: [Ris formula described below: (A is a lower alkylene group which may be substituted with lower alkyl group; Ris a hydrogen atom; Ris a hydroxyl group, an aromatic heterocyclic group which may be substituted with lower alkyl group, carbamoyl group); Ris a hydrogen atom or lower alkyl group; Ris lower alkyl group which may be substituted with 1-3 fluorine atoms, or halogen atom; Ris a five-membered aromatic monocyclic heterocyclic group, five-membered non-aromatic monocyclic heterocyclic group, (provided each heterocyclic groups contain at least one nitrogen atom and may be substituted with a lower alkyl group); and Ris a lower alkyl group, halogen atom], or pharmacologically acceptable salt thereof.

Benzoazepine derivative and medical use thereof

A dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. A compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein Rand Reach represents hydrogen, an optionally substituted C1-6 alkyl group, or &#x2014;COORwhereupon Rrepresents hydrogen or an optionally substituted C1-6 alkyl group, or R, R, and a carbon atom together represent a 3- to 6-membered cycloalkyl group, Rrepresents hydrogen or an optionally substituted C6-10 aryl group, Rrepresents a hydrogen or a cyano group, D represents &#x2014;CONR-, &#x2014;CO&#x2014; or &#x2014;NRCO&#x2014;, Rrepresents hydrogen or an optionally substituted C1-6 alkyl group, E represents &#x2014;(CH)&#x2014; whereupon m is 1 to 3, &#x2014;CHOCH&#x2014;, or &#x2014;SCH&#x2014;, n is 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.

Compound inhibiting dipeptidyl peptidase IV

Compounds of formula A and formula B:and their pharmaceutically acceptable salts, compositions comprising them, methods for their use, and their use in the preparation of medicaments. The compounds are antagonists of MCP-1 function, and are useful in the prevention and treatment of chronic or acute inflammatory or autoimmune diseases, such as multiple sclerosis, and in the prevention and treatment of allergic hypersensitivity disorders.

Antagonist of MCP-1 function, and compositions and methods of use thereof

Growing community of inventors

Kuwana, Japan

Mitsuaki Takeuchi